Wunder, D

Kolokythas, A; Betschart, C; Wunder, D; Janka, H; Stute, P (2024). Impact of vaginal estriol on serum hormone levels: a systematic review. Climacteric, 27(2), pp. 137-153. Taylor & Francis 10.1080/13697137.2023.2287624

Stute, Petra; Becker, H-G; Bitzer, J; Chatsiproios, D; Luzuy, F; von Wolff, Michael; Wunder, D; Birkhäuser, M (2015). Ultra-low dose - new approaches in menopausal hormone therapy. Climacteric, 18(2), pp. 182-186. Informa Healthcare 10.3109/13697137.2014.975198

Mueller, MD; Eberhard, M; De Geyter, C; Häberlin, F; Hohl, MK; Imesch, P; Polli, C; Possover, M; Schiessl, K; Wenger, JM; Wunder, D (2012). Konsensus: Diagnostik und Therapie der Endometriose. Frauenheilkunde aktuell FHA(2), pp. 28-34. Baden: Hohl

Wunder, D; von Wyl, S; Bischof, P; Baumann, MU; Bersinger, NA (2012). Effects of different embryo development media on hCG and progesterone release by JEG-3 and BeWo cells. Immunoanalyse & biologie spécialisée, 27(2), pp. 61-65. Issy-les-Moulineaux (F): Elsevier Masson 10.1016/j.immbio.2012.01.005

Stute, P; Becker, HG; Birkhäuser, M; Bitzer, J; chatsiproios, D; Luzuy, F; von Wolff, M; Wunder, D (2012). Ultra-Low Dose – Neue Wege in der Hormontherapie. Journal für gynäkologische Endokrinologie, 6(3), pp. 20-3. Gablitz (A): Krause & Pachernegg

Wunder, D; Huober-Zeeb, C; Moffat, R; Stiller, R; Ambrosetti, A; Xie, M; von Wolff, M (2012). Schweizerische Empfehlungen zur Fertilitätserhaltung bei Patientinnen und Patienten im fertilen Alter vor rytotoxischen Therapien. Schweizerisches Medizin-Forum SMF / Swiss medical forum / Forum médical suisse FMS(37), pp. 708-9. Basel: EMH Editores Medicorum Helveticorum

Wunder, D; Birkhäuser, MH; Bersinger, NA (2011). Soluble HLA-G concentration in follicular fluid and embryo culture medium and its impact on prediction or pregnancy. In: Jahreskongress SGGG, Lugano 2011 28 (pp. 43-50). Jahreskongress SGGG, Lugano 2011 10.1016/j.immbio.2012.10.004

Wunder, D; Neurohr, EM; Faouzi, M; Birkhäuser, M (2011). Origin of multiple pregnancies in Berne, Switzerland, between 1995 and 2006: is IVF-ICSI really the most important origin? In: Jahreskongress SGGG, Lugano 2011. Jahreskongress SGGG, Lugano 2011

Brossard, P; Boulvain, M; Coll, O; Barlow, P; Aebi-Popp, K; Bischof, P; Martinez de Tejada, B; Wunder, D (2008). Is screening for fetal anomalies reliable in HIV-infected pregnant woman? A multicentre study. AIDS, 22(15), pp. 2013-7. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/QAD.0b013e32830fbda3

Rudin, C; Burri, M; Shen, Y; Rode, R; Nadal, D; Wunder, D (2008). Long-term safety and effectiveness of ritonavir, nelfinavir and lopinavir/ritonavir in antiretroviral-experianced HIV-infected children. Pediatric infectious disease journal, 27(5), pp. 431-7. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/INF.0b013e3181646d5a

Santi, A; Wunder, D (2008). Ungewollt kinderlos. Gynäkologie(3) Neuhausen (CH): Rosenfluh Publikationen

Wunder, D; Mueller, MD (2007). Endometriose und Infertilität. Medizin für die Frau(1), pp. 26-28.

Koeferl Puorger, U P S; Buergin, M; Wunder, D; Crazzolara, S; Birkhaeuser, M H (2006). Surplus embryos in Switzerland in 2003: legislation and availability of human embryos for research. Reproductive biomedicine online, 13(6), pp. 772-7. Oxford: Elsevier 10.1016/S1472-6483(10)61023-1

Wunder, D; Bersinger, NA; Fux, C; Weber, R; Bernasconi, E; Cavassini, M; Bucher, HC; Schiffer, V; Schmid, P; Furrer, H; Swiss, HIV Cohort Study (2005). Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy. AIDS, 19(16), pp. 1837-42. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/01.aids.0000189852.21441.2a

Wunder, D; Evison, JM (2005). [Antiretroviral therapy and pregnancy]. Therapeutische Umschau, 62(1), pp. 37-42. Bern: Huber 10.1024/0040-5930.62.1.37